RIGEL PHARMACEUTICALS INC - 8-K Filing
On May 11, 2026, Rigel Pharmaceuticals entered into a $70 million upfront payment License Agreement with Arvinas and Pfizer to exclusively develop and commercialize VEPPANU (vepdegestrant), an FDA-approved treatment for advanced breast cancer. The deal includes up to $320 million in milestone payments, tiered royalties on net sales ranging from mid-teens to mid-twenties percentages, and a $40 million cap on development cost reimbursements. (Items: 1.01 Entry into a Material Definitive Agreement)
Tickers: $RIGL